<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03618238</url>
  </required_header>
  <id_info>
    <org_study_id>XHLSG-NK-1604</org_study_id>
    <nct_id>NCT03618238</nct_id>
  </id_info>
  <brief_title>Anlotinib for Advanced and Refractory Natural Killer /T-cell Lymphoma</brief_title>
  <official_title>A Pilot Study of Anlotinib for the Evaluation of Safety and Efficacy in Patients With Stage IV Natural Killer/T-cell Lymphoma and Refractory to L-asparaginase Based Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of anlotinib in patients&#xD;
      with stage IV extranodal natural killer/T-cell lymphoma, nasal type.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Extranodal natural killer/T-cell lymphoma (ENKTCL), nasal type, is a rare subtype of&#xD;
      non-Hodgkin lymphoma (NHL) with relatively high incidence in China. L-asparaginase based&#xD;
      chemotherapy improved overall response and prolonged the long-term survival for patients with&#xD;
      stage IV. But the treatment for the patients with advanced disease and resistant to&#xD;
      L-asparaginase based chemotherapy has not been established. The overall survival for these&#xD;
      patients are very poor. This study is designed to evaluate the efficacy and safety of&#xD;
      anlotinib in patients with stage IV ENKTCL and refractory to L-asparaginase based&#xD;
      chemotherapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 25, 2018</start_date>
  <completion_date type="Actual">April 30, 2021</completion_date>
  <primary_completion_date type="Actual">April 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>drug</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>12 weeks after the initiation of anlotinib treatment</time_frame>
    <description>The treatment response will be assessed every 12 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment-Related Adverse Events as Assessed by CTCAE v4.0</measure>
    <time_frame>Day 1 of each course and then every 3 months for 2 years</time_frame>
    <description>Treatment-Related Adverse Events will be assessed and graded by NCI CTCAE v4.0.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type</condition>
  <arm_group>
    <arm_group_label>Anlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients will be given anlotinib 12 mg daily for continus 14 days every 21 days until disease progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib</intervention_name>
    <description>12 mg daily for continus 14 days every 21 days</description>
    <arm_group_label>Anlotinib</arm_group_label>
    <other_name>Anlotinib Hydrochloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathological diagnosis of extranodal natural killer/T-cell lymphoma, nasal type.&#xD;
&#xD;
          -  stage IV disease and resistant to L-asparaginase-based combined&#xD;
             chemotherapy.(Definition of L-asparaginase resistance: Progression during treatment or&#xD;
             no response to treatment).&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG ) performance status 0~3.&#xD;
&#xD;
          -  Preserved organ functions for: absolute neutrophil counter (ANC)&gt;1.0×109/L,&#xD;
             Platelet&gt;50×109/L, hemoglobin&gt;80g/L, total bilirubin (TBIL)&lt;2×ULN, alanine&#xD;
             transaminase (ALT)&lt;2×ULN, normal serum creatinine，fibrinogen≥1.0g/L, LVEF≥50%.&#xD;
&#xD;
          -  Signed Informed consented.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients with a disease resistant to L-asparaginase but may benefit from a&#xD;
             radiotherapy.&#xD;
&#xD;
          -  HIV, hepatitis virus C (HCV), or active hepatitis virus B (HBV) infection with HBV&#xD;
             DNA≥105 copies/ml.&#xD;
&#xD;
          -  Significant complications: autoimmune disease, severe infection, or liver cirrhosis,&#xD;
             hemophagocytic lymphohistiocytosis, disseminated intravascular coagulation,&#xD;
             uncontrolled hypertension or diabetes, hemorrhagic or thrombotic events within 6&#xD;
             months.&#xD;
&#xD;
          -  Mental disorders.&#xD;
&#xD;
          -  Pregnant or lactation&#xD;
&#xD;
          -  Peptic ulcer&#xD;
&#xD;
          -  Enrolled in other trial treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rong Tao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Jiao Tong University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Xinhua Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 1, 2018</study_first_submitted>
  <study_first_submitted_qc>August 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2018</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Rong Tao</investigator_full_name>
    <investigator_title>Clinical Professor and Associate Director of Department of Hematology</investigator_title>
  </responsible_party>
  <keyword>anlotinib</keyword>
  <keyword>L-asparaginase resistant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

